Vinge advises Embellence Group AB (publ) (“Embellence Group”) in connection with the listing on Nasdaq First North Premier Growth Market. The offering circular was published on 15 March 2021 and first day of trading was on 24 March 2021.
Vinge has advised CELLINK AB (publ) in connection with a directed issue of covertibles of SEK 1.5 billion and a directed issue of B-shares of SEK 1.5 billion, in total SEK 3 billion.
Vinge has advised Azelio in connection with a directed share issue whereby Azelio raises approximately SEK 596 million in issue proceeds before transaction costs.
The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 1,106 million, before issue costs.
Vinge has advised Nick’s, a food-tech brand offering sugar free snacks and ice cream, in connection with its largest investment round of USD 30 million.
The banks acted as arrangers and bookrunners in connection with Heimstaden AB’s (publ) issuance of EUR 350,000,000 senior unsecured bonds, within a framework amount of EUR 450,000,000.
Vinge advises Net Insight AB (publ) in connection with the signing of an agreement to divest its Resource Optimization business area, doing business as “ScheduALL“ to Xytech Systems Corp.
Vinge has advised VNV Global AB (publ), an investment company listed on Nasdaq Stockholm, in connection with a directed share issue whereby VNV Global receives approximately SEK 1,166 million in issue proceeds.
Vinge has advised CELLINK AB (publ) in connection with the acquisition of all shares in Ginolis Oy. Ginolis conducts operations in relation to automated diagnostics and provides advanced robotic solutions to the medical- and diagnostics industries.
Vinge advises Atlas Antibodies AB (majority owned by Patricia Industries, a part of Investor AB), in connection with its acquisition of HistoCyte Laboratories Ltd.
The recapitalisation is carried out to strengthen ITAB’s capital structure to reduce the financial leverage of the group, to invest in the One ITAB transformation plan and to provide sufficient headroom to the business given the Covid-19 situation.
Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore Pharma receives gross proceeds of SEK 336 million.
